Patent application number | Description | Published |
20100196308 | VITAMIN D3 AND ANALOGS THEREOF FOR ALLEVIATING SIDE EFFECTS ASSOCIATED WITH CHEMOTHERAPY - The present disclosure relates to the use of vitamin D compounds, such as vitamin D3, or analogs and/or metabolites thereof, to modulate bone marrow progenitors and stromal cells prior to the administration of antineoplastic agents. The methods of the present disclosure may ameliorate myelosuppression by increasing the availability of pluripotent stem cell progenitors, and can be used in combination with standard therapy (e.g. granulocyte stimulating factor) to increase proliferation of myeloid cells and/or improve their mobilization from the bone marrow, thereby diminishing the dose and administration of colony-stimulating factors (CSFs) as well as the recuperation time following chemotherapy. | 08-05-2010 |
20110020312 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for treating metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | 01-27-2011 |
20110027247 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described. | 02-03-2011 |
20110027811 | ASSAY SYSTEM FOR THE ASSESSMENT OF ONCOGENICITY, TUMOR PROGRESSION, AND TREATMENT EFFICACY - Systems and kits are provided which are capable of determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Such systems and kits utilize assays to examine the levels of apoptotic markers, angiogenesis markers, immunomodulation markers, and cell cycle markers and can compare samples from a patient taken at different times to determine the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Methods for determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment with such systems and kits are also provided. | 02-03-2011 |
20110059917 | VITAMIN D3 AND ANALOGS THEREOF FOR TREATING ALOPECIA - The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication. | 03-10-2011 |
20110064747 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided. | 03-17-2011 |
20110110914 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | 05-12-2011 |
20110123986 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for diagnosing metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | 05-26-2011 |
20110123987 | METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for diagnosing onocological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | 05-26-2011 |
20110136231 | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS - The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis. | 06-09-2011 |
20110229554 | INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOF - Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C. to form a hydrophobic active agent/water/stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent/water/stabilizer/reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent/water/stabilizer/reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs. | 09-22-2011 |
20120164215 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 06-28-2012 |
20120201801 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 08-09-2012 |
20120258874 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF - Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building. | 10-11-2012 |
20120269867 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM TUMORS - The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor. | 10-25-2012 |
20120309086 | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS - The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q10 or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q10 or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q10 in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis. | 12-06-2012 |
20120321698 | INHALABLE PHARMACEUTICAL COMPOSITIONS - Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQ10) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output. | 12-20-2012 |
20130189237 | CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 07-25-2013 |
20130202683 | TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY - The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. | 08-08-2013 |
20130259847 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF - Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building | 10-03-2013 |
20130266557 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided. | 10-10-2013 |
20130315885 | INTEROGATORY CELL-BASED ASSAYS FOR IDENTIFYING DRUG-INDUCED TOXICITY MARKERS - Described herein is a discovery Platform Technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building. | 11-28-2013 |
20140017317 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 - The invention provides methods and compositions for treatment of a subject with a solid tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject has failed at least one prior chemotherapeutic regimen. | 01-16-2014 |
20140023627 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 01-23-2014 |
20140038302 | METHODS AND KITS FOR DETECTION OF COENZYME Q10 - The invention provides methods for rapid and quantitative extraction and detection of coenzyme Q10 in a sample readily adaptable to high throughput screening methods. The invention further provides reagents and kits for practicing the methods of the invention. | 02-06-2014 |
20140038838 | USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER - The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention. | 02-06-2014 |
20140100128 | USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS AND IN THE DIAGNOSIS AND MONITORING OF CARDIOMYOPATHY AND CARDIOVASCULAR DISEASE - The invention provides methods for the diagnosis and prognosis of cardiovascular disease, and for monitoring of the treatment of cardiovascular disease, including heart failure and cardiomyopathy. The invention further provides methods for identifying an agent for treating cardiomyopathy or heart failure, for identifying a cardiotoxic agent, and for identifying a rescue agent to reduce or prevent drug-induced toxicity, by using one or more biomarkers selelcted from the group consisting of CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; and PC-LI-183-D18:22-22:6, or any of the other biomarkers provided herein. The invention further provides kits for practicing the methods of the invention. | 04-10-2014 |
20140154266 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA - The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90β, expression and activity level. | 06-05-2014 |
20140239525 | INHALABLE PHARMACEUTICAL COMPOSITIONS - Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQIO) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output. | 08-28-2014 |
20140255372 | CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 09-11-2014 |
20140302014 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES - Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy. | 10-09-2014 |
20150010614 | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS - The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic add to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apopotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis. | 01-08-2015 |
20150023940 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described. | 01-22-2015 |
20150023949 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER - Methods for treatment and diagnosis of pervasive developmental disorders in humans are described. | 01-22-2015 |